Table 6.
Trial | Bettencourt et al. 84 | Rochitte et al. 85 | Cury et al. 86 | George et al.95 | Magalhaes et al.96 | Pontone et al. 83 |
---|---|---|---|---|---|---|
Study design | Prospective, single-centre study | Prospective, multicentre, international study | Randomized, multicentre, multivendor study | Prospective, multicentre, international study | Prospective, multicentre, international study | Prospective, single-centre study |
Sample size | 101 | 381 | 110 | 381 | 381 | 147 |
Clinical setting | Stable CAD | Stable CAD | Stable CAD | Stable CAD | Stable CAD | Stable CAD |
CT scanner | 64-slice CT | 320-slice CT | Multivendor | 320-slice CT | 320-slice CT | 256-slice CT |
Reference standard | FFR ≤ 0.80 or LM disease or vessel occlusion on ICA | QCA ≥ 50% and SPECT | SPECT | QCA | QCA ≥ 50% and SPECT | QCA > 80% and/or invasive FFR ≤0.80 |
Level of analysis | Vessel (n = 303) | Vessel (n = 1143) | Patient (n = 110) | Vessel (n = 1143) | Vessel (n = N/A) | Vessel (n = 432) |
Sensitivity (95% CI) | 55 (46–61) | 61 (55–67)a | 90 (71–100) | 78 (73–82) | 58 (51–64)a | 92 (87–97)a |
Specificity (95% CI) | 95 (93–97) | 83 (80–86)a | 84 (77–91) | 62 (58–67) | 86 (83–88)a | 95 (92–97)a |
PPV (95% CI) | 78 (66–88) | 52 (45–58)a | 36 (17–55) | 58 (53–63) | 55 (48–61)a | 87 (81–92)a |
NPV (95% CI) | 87 (84–89) | 88 (85–90)a | 99 (97–100) | 81 (76–85) | 87 (84–90)a | 97 (95–99)a |
CCTA + CTP.
CAD, coronary artery disease; CI, confidence interval; CT, computed tomography; FFR, fractional flow reserve; ICA, invasive coronary angiography; LM, left main; N/A, not available; NPV, negative predictive value; PPV, positive predictive value; QCA, quantitative coronary angiography; SPECT, single-photon emission computed tomography.